Antibody and antigen responses to Lufotrelvir vs placebo day 1–90. by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses to Ensovibep vs placebo day 1–90. by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses to nMAb vs placebo day 1–90 for Sotrovimab. by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses to nMAb vs placebo day 1–90 for Amubarvimab/ Romlusevimab. by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses to nMAb vs placebo day 1–90 for Tixagevimab/ Cilgavimab. by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses to nMAb vs placebo day 1–90 for Bamlanivimab. by Elizabeth S. Munroe (21568166)

Subjects:

Longitudinal antibody and antigen responses to treatment vs placebo day 1–90 for nMAbs, among patients alive and with day 90 antibody and antigen measures (Sensitivity Analysis). by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses by baseline anti-spike neutralizing response assay positivity. by Elizabeth S. Munroe (21568166)

Subjects:

Linearity of ACER3 activity assay. by Jae Kyo Yi (13570063)

Baseline patient characteristics across neutralizing monoclonal antibody trials. by Elizabeth S. Munroe (21568166)

Subjects:

Quantitative antibody and antigen responses to nMAb vs placebo day 1-90: Pooled analysis of neutralizing monoclonal antibodies. by Elizabeth S. Munroe (21568166)

Subjects:

Longitudinal antibody and antigen responses to treatment vs placebo day 1–90 for neutralizing monoclonal antibodies, among patients alive and with day 90 antibody and antigen measu... by Elizabeth S. Munroe (21568166)

Subjects:

Effect of anti-<i>Leishmania</i> compounds added to a sugar diet on females of <i>Lu. longipalpis</i> pre and post-blood feeding. by Tainá Neves Ferreira (21601579)

Overview of the six original ACTIV-3/TICO trials. by Elizabeth S. Munroe (21568166)

Subjects:

eIF5a is up-regulated in unruptured AAAs and decreased in ruptured AAAs. by Dong Ma (584680)

Subjects:

P-Rex is required for a late phase of stimulus-evoked cerebellar LTP. by Claire Jackson (362873)

The kinetics of ACER3 and mutants. by Jae Kyo Yi (13570063)

Decrease in Akt/mTOR signaling and cell proliferation in <i>Tgfbr1/Pten</i> 2cKO ASCC after rapamycin treatment. by Zhi-Jun Sun (467107)

“…Rapamycin treatment increased protein levels of cleaved caspase-3 (CL-Casp3) and cleaved PARP (CL-PARP). Rapa; Rapamycin, (D), Quantification for relative mRNA levels of Akt1, Rps6, Birc5 and Mki67 shows decreased mRNA levels in rapamycin-treated group (n = 3) as compared with vehicle-treatedgroup(n = 5). …”

An outline of our methodology. by Krishna Bathina (12883820)

Predicted acceptance probabilities to a top 5 journal against Alma mater ranking at the time of graduation using splines. by Sergey V. Popov (6719075)